Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02209012 · ClinicalTrials.gov registry record
Twelve Month Follow-Up of CP0108
A clinical trial, sponsored by DUSA Pharmaceuticals.
- Completed
- Registry status
- 206
- Enrollment target
NCT02209012 is a clinical trial that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 206 participants.
The verdict
NCT02209012 has completed, sponsored by DUSA Pharmaceuticals.
- COMPLETED
- Registry status
- 206 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the long-term safety and efficacy of Levulan PDT in subjects with multiple actinic keratosis of the upper extremities who received treatment as part of the DUSA CP0108 study.
Interventions
- DRUG Aminolevulinic Acid (ALA)
- DRUG Topical Solution Vehicle
- DEVICE BLU-U Blue Light Photodynamic Therapy Illuminator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02209012
The ClinicalTrials.gov registry entry for NCT02209012 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DUSA Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aminolevulinic Acid (ALA) is the first listed.
NCT02209012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02209012 about?
NCT02209012 is a clinical study titled "Twelve Month Follow-Up of CP0108". The purpose of this study is to determine the long-term safety and efficacy of Levulan PDT in subjects with multiple actinic keratosis of the upper extremities who received treatment as part of the DUSA CP0108 study.
What is the current status of trial NCT02209012?
This trial is currently completed. The enrollment target is 206 participants. The study started on 2014-08. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02209012?
The interventions under investigation include: Aminolevulinic Acid (ALA) (DRUG), Topical Solution Vehicle (DRUG), BLU-U Blue Light Photodynamic Therapy Illuminator (DEVICE).
Who is sponsoring clinical trial NCT02209012?
This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.